Overview

A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body

Status:
Completed
Trial end date:
2021-01-10
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the basic pharmacokinetics of BI 1358894 and its metabolites, total radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of [14C] BI 1358894 in Part 1 and to investigate the pharmacokinetics of BI 1358894 and its metabolite(s) following multiple-dose treatment over 21 days with non- radiolabelled compound of BI 1358894 in Part 2.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim